Equities research analysts expect Syneos Health (NASDAQ:SYNH) to report earnings of $0.61 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Syneos Health’s earnings, with the highest EPS estimate coming in at $0.65 and the lowest estimate coming in at $0.59. Syneos Health posted earnings of $0.64 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 4.7%. The firm is expected to issue its next quarterly earnings results on Thursday, July 26th.
According to Zacks, analysts expect that Syneos Health will report full year earnings of $2.67 per share for the current fiscal year, with EPS estimates ranging from $2.63 to $2.80. For the next year, analysts forecast that the company will post earnings of $3.09 per share, with EPS estimates ranging from $3.00 to $3.20. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Syneos Health.
Get Syneos Health alerts:Syneos Health (NASDAQ:SYNH) last released its quarterly earnings results on Wednesday, May 9th. The company reported $0.55 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.04. The business had revenue of $761.00 million during the quarter, compared to analyst estimates of $767.24 million. Syneos Health had a negative net margin of 5.50% and a positive return on equity of 8.79%. The firm’s revenue was up 201.9% on a year-over-year basis.
Several analysts have commented on the stock. Barclays reissued an “equal weight” rating and set a $43.00 price target (up from $40.00) on shares of Syneos Health in a research report on Thursday, March 1st. SunTrust Banks increased their price target on shares of Syneos Health to $55.00 and gave the company a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research lowered shares of Syneos Health from a “buy” rating to a “hold” rating in a research report on Wednesday, March 14th. Mitsubishi UFJ Financial Group began coverage on shares of Syneos Health in a research report on Friday, April 20th. They set an “overweight” rating and a $50.00 price target for the company. Finally, ValuEngine lowered shares of Syneos Health from a “hold” rating to a “sell” rating in a research report on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $50.40.
Shares of SYNH stock traded up $0.25 during mid-day trading on Thursday, hitting $40.40. 574,751 shares of the stock traded hands, compared to its average volume of 847,112. The firm has a market cap of $4.15 billion, a price-to-earnings ratio of 18.28, a PEG ratio of 0.98 and a beta of 0.79. Syneos Health has a 52-week low of $31.10 and a 52-week high of $61.10. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.09 and a current ratio of 1.09.
Several institutional investors have recently made changes to their positions in the stock. Wesbanco Bank Inc. purchased a new position in shares of Syneos Health in the 1st quarter valued at approximately $998,000. CIBC World Markets Inc. purchased a new position in shares of Syneos Health in the 1st quarter valued at approximately $231,000. Xact Kapitalforvaltning AB purchased a new position in shares of Syneos Health in the 1st quarter valued at approximately $270,000. Royal Bank of Canada purchased a new position in shares of Syneos Health in the 1st quarter valued at approximately $656,000. Finally, Legal & General Group Plc purchased a new position in shares of Syneos Health in the 1st quarter valued at approximately $1,933,000.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Get a free copy of the Zacks research report on Syneos Health (SYNH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment